Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on SKANDINAVISKA ENSKILDA BAN-A. We currently have 2 research reports from 1 professional analysts.
|17Mar17 17:00||GNW||SEB issues Additional Tier 1 Capital|
|15Mar17 08:00||GNW||SEB's China Financial Index: Significant uptick in new orders for Nordic companies in China|
|07Mar17 07:30||GNW||SEB's annual reporting published|
|21Feb17 12:33||GNW||Welcome to Annual General Meeting in Skandinaviska Enskilda Banken AB on 28 March 2017|
|14Feb17 10:00||GNW||SEB: Investment Outlook: Higher growth and inflation rates|
|08Feb17 07:09||GNW||SEB appoints Johan Torgeby new President and CEO|
|07Feb17 09:00||GNW||SEB: Nordic Outlook: Complex cyclical and political forces - Broader-based Swedish growth- Riksbank rate hike in 2017|
Frequency of research reports
Research reports on
SKANDINAVISKA ENSKILDA BAN-A
SKANDINAVISKA ENSKILDA BAN-A
No possible extrapolation but net interest income reassuring...
20 Oct 16
SEB published its Q3 results. Total income was better than expectations (at SEK10.79bn or 2.5% above consensus) but only on the back of strong trading income while core (and stable) revenues, be it net interest income or net fees, were roughly in line with expectations. With total expenses in line but a much better cost of risk, profit before tax was 10% above expectations. CET1 at 18.6% is just 10bp lower versus Q2 16.
Positive on earnings and capital
04 Feb 16
SEB released its Q415 earnings this morning. These are quite strong as profit before tax is 15% higher than expectations. CET1 ratio also turned out quite strong at 18.8% (versus 17.8% Q315). Dividend is higher than expectations at SEK5.25ps (versus SEK5ps consensus).
Another positive verdict
20 Mar 17
Burford’s results for 2016 produced another outstanding set of figures. Revenue grew by 60% to $163.4m with strong growth in the litigation finance business and an additional boost from a secondary sale in the Petersen case. On an underlying basis net income grew to $114m, a 75% increase despite the investment in growing capacity which increased costs. A combination of ongoing investment and gains and increases on valuation saw the fair value of the litigation assets increase 67% to $559m, underpinned by a growth in invested capital to $394m. With the results statement there was an announcement of a further sale of 9% of the Petersen case at a valuation of 20 times the cost of investment.
N+1 Singer - Morning Song 22-03-2017
22 Mar 17
Carador Income Fund (CIFU LN) Premium rating restored, high levels of refinancing activity | Cello Group (CLL LN) Outlook getting brighter – watch Pulsar | Eckoh (ECK LN) Largest ever US secure payments win | eg solutions (EGS LN) Full year results in line | Futura Medical (FUM LN) Licensing deal for CSD500 in Portugal | Verona Pharma (VRP LN) Global agreement with QuintilesIMS to support development of RPL554 | Xaar (XAR LN) 2016 results slightly ahead, reduced visibility in 2017
Small Cap Breakfast
21 Mar 17
First Sentinel—Investment company expecting NEX admission/introduction on 24 March. £636k raised pre-IPO. BioPharma Credit—Expected Gross Initial Acquisition Proceeds now c.$338m. Gross Cash Proceeds capped at $423m with placing and open offer. Results expected 23 March with admission now due 30 march. Tufton Oceanic Assets- The Company intends to invest in a diversified portfolio of second hand commercial sea-going vessels where the Investment Manager believes that an attractive opportunity exists in shipping. $150m raise. Admission 3 April.